GLUCOPHAGE TABLET

País: Canadá

Idioma: inglés

Fuente: Health Canada

Ingredientes activos:

METFORMIN HYDROCHLORIDE

Disponible desde:

SANOFI-AVENTIS CANADA INC

Código ATC:

A10BA02

Designación común internacional (DCI):

METFORMIN

Dosis:

500MG

formulario farmacéutico:

TABLET

Composición:

METFORMIN HYDROCHLORIDE 500MG

Vía de administración:

ORAL

Unidades en paquete:

100/500

tipo de receta:

Prescription

Área terapéutica:

BIGUANIDES

Resumen del producto:

Active ingredient group (AIG) number: 0101773001; AHFS:

Estado de Autorización:

APPROVED

Fecha de autorización:

2006-05-12

Ficha técnica

_ _
_ _
_Page 1 of 39_
PRODUCT MONOGRAPH
Pr
GLUCOPHAGE
®
Metformin Hydrochloride Tablets
Manufacturer’s standard
500 mg, 850 mg
Oral Antihyperglycemic Agent
®
Registered trade mark of Merck Santé. Used under licence
sanofi-aventis Canada Inc.
2905 Place Louis-R.-Renaud
Laval (Québec) H7V 0A3
Date of revision :
March 2, 2018
Submission Control No.: 211582
_ _
_ _
_Page 2 of 39_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY
PRODUCT
INFORMATION................................................................................
3
INDICATIONS
AND
CLINICAL
USE......................................................................................
3
CONTRAINDICATIONS
..........................................................................................................
4
WARNINGS
AND
PRECAUTIONS
.........................................................................................
5
ADVERSE
REACTIONS
.........................................................................................................
13
DRUG
INTERACTIONS
.........................................................................................................
15
DOSAGE
AND
ADMINISTRATION
.....................................................................................
18
OVERDOSAGE........................................................................................................................
20
ACTION
AND
CLINICAL
PHARMACOLOGY
....................................................................
21
STORAGE
AND
STABILITY
.................................................................................................
22
DOSAGE
FORMS,
COMPOSITION
AND
PACKAGING ..................................................... 22
PART II: SCIENTIFIC INFORMATION
...............................................................................
23
PHARMACEUTICAL
INFORMATION
.................................................................................
23
CLINICAL
TRIALS
..